Over 90% of potential anti-cancer drug candidates results in translational failures in clinical
trials. The main reason for this failure can be attributed to the non-accurate pre-clinical …

Introduction The high failure rate in drug discovery remains a costly and time-consuming
challenge. Improving the odds of success in the early steps of drug development requires …

Cancer is a multifaceted pathology, where cellular and acellular players interact to drive
cancer progression and, in the worst-case, metastasis. The current methods to investigate …

For decades, 2D cell culture format on plastic has been the main workhorse in cancer
research. Though many important understandings of cancer cell biology were derived using …

Advances in understanding many of the fundamental mechanisms of cancer progression
have led to the development of molecular targeted therapies. While molecular targeted …

Cancer is a disorder characterized by an uncontrollable overgrowth and a fast-moving
spread of cells from a localized tissue to multiple organs of the body, reaching a metastatic …

High attrition of new oncology drug candidates in clinical trials is partially caused by the poor
predictive capacity of artificial monolayer cell culture assays early in drug discovery …

Abstract Three-dimensional (3D) cell cultures have emerged as valuable tools in cancer
research, offering significant advantages over traditional two-dimensional (2D) cell culture …

There is cumulating evidence that in vitro 3D tumor models with increased physiological
relevance can improve the predictive value of pre‐clinical research and ultimately contribute …

The tumor microenvironment contributes significantly to tumor initiation, progression, and
resistance to chemotherapy. Much of our understanding of the tumor and its …